press releases

September 21, 2015 07:00 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–NovoCure Limited, a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today the launch of its initial public offering of 12,500,000 shares of its common… Read More

September 21, 2015 07:00 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–NovoCure Limited, a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today the launch of its initial public offering of 12,500,000 shares of its common… Read More

September 09, 2015 07:00 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that the latest data from the EF-14 randomized phase 3 trial of Tumor Treating Fields (TTFields) in newly diagnosed glioblastoma (GBM)… Read More

September 09, 2015 07:00 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that the latest data from the EF-14 randomized phase 3 trial of Tumor Treating Fields (TTFields) in newly diagnosed glioblastoma (GBM)… Read More

September 09, 2015 07:00 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that the latest data from the EF-14 randomized phase 3 trial of Tumor Treating Fields (TTFields) in newly diagnosed glioblastoma (GBM)… Read More

Optune, a Tumor Treating Fields delivery system, provides a novel, non-invasive treatment for recurrent glioblastoma, the most common and deadly malignant primary brain cancer Optune, a Tumor Treating Fields delivery system, provides a novel, non-invasive treatment for recurrent glioblastoma, the most common and deadly malignant primary brain… Read More

Optune, a Tumor Treating Fields delivery system, provides a novel, non-invasive treatment for recurrent glioblastoma, the most common and deadly malignant primary brain cancer Optune, a Tumor Treating Fields delivery system, provides a novel, non-invasive treatment for recurrent glioblastoma, the most common and deadly malignant primary brain… Read More

Optune, a Tumor Treating Fields delivery system, provides a novel, non-invasive treatment for recurrent glioblastoma, the most common and deadly malignant primary brain cancer Optune, a Tumor Treating Fields delivery system, provides a novel, non-invasive treatment for recurrent glioblastoma, the most common and deadly malignant primary brain… Read More

September 04, 2015 10:24 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that its ongoing and future clinical trial designs in lung cancer will be presented at the 16th World Conference on Lung… Read More